Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors
Joseph J. Gingell, Tayla A. Rees, Erica R. Hendrikse, et al.
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 2, pp. 296-304
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 305
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
Linda Al‐Hassany, Peter J. Goadsby, A.H. Jan Danser, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 284-294
Closed Access | Times Cited: 99
Shared and independent roles of CGRP and PACAP in migraine pathophysiology
Adisa Kuburas, Andrew F. Russo
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 49
Migraine therapeutics differentially modulate the CGRP pathway
Minoti Bhakta, Trang Vuong, Tetsuya Taura, et al.
Cephalalgia (2021) Vol. 41, Iss. 5, pp. 499-514
Open Access | Times Cited: 80
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 6, pp. 627-641
Closed Access | Times Cited: 60
Mediators of Amylin Action in Metabolic Control
Christina N. Boyle, Yi Zheng, Thomas A. Lutz
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2207-2207
Open Access | Times Cited: 33
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab
Tessa de Vries, Eloísa Rubio‐Beltrán, Antoon van den Bogaerdt, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 12, pp. 1720-1733
Open Access | Times Cited: 6
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 417-440
Open Access | Times Cited: 40
CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?
Michael L. Garelja, Christopher S. Walker, Debbie L. Hay
British Journal of Pharmacology (2021) Vol. 179, Iss. 3, pp. 454-459
Open Access | Times Cited: 34
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins
Ilana B. Kotliar, Emily Lorenzen, Jochen M. Schwenk, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 1-34
Open Access | Times Cited: 28
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
Michael L. Garelja, Debbie L. Hay
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1093-1104
Open Access | Times Cited: 23
Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine
Simone de Vries Lentsch, Britt W. H. van der Arend, Irene de Boer, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 2
Open Access | Times Cited: 13
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
Nina Sonne, M.A. Karsdal, Kim Henriksen
Molecular Metabolism (2020) Vol. 46, pp. 101109-101109
Open Access | Times Cited: 39
Pharmacological characterisation of mouse calcitonin and calcitonin receptor‐like receptors reveals differences compared with human receptors
Michael L. Garelja, Rebekah L. Bower, Margaret A. Brimble, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 3, pp. 416-434
Open Access | Times Cited: 28
CGRP and the Calcitonin Receptor are Co-Expressed in Mouse, Rat and Human Trigeminal Ganglia Neurons
Tayla A. Rees, Andrew F. Russo, Simon J. O’Carroll, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 21
Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD
Andrew M. Strassman, Agustín Melo-Carrillo, Timothy T. Houle, et al.
Cephalalgia (2022) Vol. 42, Iss. 9, pp. 933-943
Open Access | Times Cited: 19
Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
Michał Fila, Jan Chojnacki, Piotr Sobczuk, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 289-289
Open Access | Times Cited: 11
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
Zoe Tasma, Andrew Siow, Paul W. R. Harris, et al.
Headache The Journal of Head and Face Pain (2025)
Open Access
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Zoe Tasma, Michael L. Garelja, Aqfan Jamaluddin, et al.
Pharmacology & Therapeutics (2025), pp. 108846-108846
Open Access
Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases
Hannah Louise Zakariassen, Linu M. John, Thomas A. Lutz
Basic & Clinical Pharmacology & Toxicology (2020) Vol. 127, Iss. 3, pp. 163-177
Open Access | Times Cited: 21
Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics
T. Pooventhiran, Ephraim Felix Marondedze, Penny P. Govender, et al.
Journal of Molecular Modeling (2021) Vol. 27, Iss. 10
Open Access | Times Cited: 18
Is calcitonin gene-related peptide a reliable biochemical marker of migraine?
Betel Tesfay, William Kristian Karlsson, Rogelio Domínguez-Moreno, et al.
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 343-352
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top